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Abstract
Background and Aims Utilization and safety of cannabidiol (CBD) in patients with autoimmune hepatitis (AIH) are currently 
unknown. We aimed to identify the frequency of CBD use, impact on symptoms, and safety profile.
Methods An invitation to complete a CBD-specific questionnaire was posted every other day to well-established autoimmune 
hepatitis Facebook communities (combined membership of 2600 individuals) during a 10-day study period. Age ≥ 18 years 
and an AIH diagnosis by a physician were the eligibility criteria for participation in the survey.
Results In total, 371 AIH patients (median age 49 years, 32% reported advanced fibrosis) completed the questionnaire. 
Respondents were 91% women, 89% Caucasian, and 89% from North America. Ninety-three (25%) respondents were ever 
CBD users, with 55 of them (15% of the survey responders) identified as current users. Among ever users, 45.7% reported 
their treating doctors were aware of their CBD use. The most common reason cited for CBD use was pain (68%), poor sleep 
(62%), and fatigue (38%). Most respondents using CBD for these symptoms reported a significant improvement in pain (82%), 
sleep (87%), and fatigue (61%). In ever CBD users, 17.3% were able to stop a prescription medication because of CBD use: 
pain medication (47%), immunosuppression (24%), and sleep aids (12%). Side effects attributed to CBD use were reported 
in 3% of CBD users, yet there were no reported emergency department visits or hospitalizations.
Conclusion CBD use was not uncommon in patients with AIH, and its use was associated with reports of improvement in 
extrahepatic symptoms.
Keywords AIH · CBD · Fatigue · Pain
Introduction
Autoimmune hepatitis (AIH) is a chronic liver disorder in 
which clinical presentation can vary widely from non-spe-
cific extrahepatic symptoms to fulminant hepatic failure [1]. 
Immunosuppressive therapy is the mainstay of treatment for 
AIH [2] and has been associated with improvement in symp-
toms, liver biochemistries, and histologic inflammation [3]. 
Unfortunately, impairment of emotional and mental health is 
prevalent in AIH and can diminish the health-related quality 
of life in these patients [4, 5]. The etiology of this phenom-
enon remains unclear, yet may be linked to common AIH 
symptoms such as pain, fatigue, and sleep disturbances [6, 
7].
Complementary and alternative medical strategies 
have become a popular approach for patients with chronic 
diseases [8] and often are utilized to target pain, anxiety, 
and depression [9]. Cannabidiol (CBD), one of the more 
than 110 different cannabinoids that have been isolated 
by researchers from Cannabis Sativa plant, is more com-
monly known as marijuana. However, CBD does not cause 
intoxication or euphoria (the “high”) that comes from tet-
rahydrocannabinol (THC), the psychoactive cannabinoid. 
CBD has received lot of recent attention after Food & 
Drug Administration’s (FDA) approval of purified CBD, 
Epidiolex, as treatment for two rare forms of epilepsy [10]. 
Utilization of CBD outside this indication for a variety of 
symptoms such as pain, glaucoma, anxiety has had mixed 
reviews and is not recognized by the FDA as an ailment 
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that CBD can treat [11, 12]. Furthermore, there is a shift in 
legal status after the 2018 Farm Bill allowing for expanded 
cultivation of industrial hemp and permission for the 
transfer of hemp-derived products across state lines for 
commercial or other purposes. Removal of hemp-derived 
products from Schedule 1 status has led to an explosion 
of CBD-related products to be available legally in some 
states. However, adding CBD, regardless of its extraction 
source, to food, beverages, and dietary supplements, is 
currently not permitted by the FDA.
Research in a rare disease is challenging due to limited 
access to patients. However, patients with rare disease 
are increasingly colocated virtually online through social 
media outlets such as Facebook, Instagram or through tra-
ditional Web sites that promote peer-to-peer connections 
(www.patie ntsli keme.com) or nonprofit organizations 
dedicated to their disease [13]. Our group in the past has 
successfully leveraged social media to conduct research 
in online cohorts of autoimmune hepatitis by deploying 
surveys that even included confirmation of diagnosis by 
procuring medical records and biosamples [14, 15]. In the 
current study, we aimed to identify the frequency of CBD 
use in AIH patients and assess the impact on symptoms 
and safety profile using two large AIH-specific social 
media groups.
Methods
We conducted a cross-sectional survey study using AIH 
social media communities on Facebook (www.faceb ook.
com): Autoimmune Hepatitis Research Network and 
Autoimmune Hepatitis Association. We have previously 
described this approach for collecting patient-reported dis-
ease attributes [16] as well as recruitment to an ongoing 
AIH biorepository at Indiana University [15]. At the time of 
the survey, the combined membership of these online com-
munities was over 2600. An online invitation to participate 
in a research study collecting information on CBD use was 
posted on these groups every other day for 10 days (Octo-
ber 2018). The survey included a link directed to an IRB-
approved Redcap database for data collection.
Survey Tool
The questionnaire was composed of 33 questions (Sup-
plementary Table 1) assessing participant demographics, 
AIH disease characteristics, history of and current CBD 
use, and adverse effects. Participants were required to be 
aged ≥ 18 years and have previously received a diagnosis of 
AIH from a medical doctor.
Statistical Analysis
Survey data were analyzed using SPSS 25 software. Con-
tinuous variables were summarized as median and the 25th 
and 75th percentiles, and p values were obtained with the 
Wilcoxon rank-sum test.
Results
A total of 371 participants with AIH completed the ques-
tionnaire during the study period. The group was predomi-
nantly female (91.4%) and Caucasian (88.9%) and had a 
median age of 49 years at survey completion (Table 1). 
The median age of AIH diagnosis was 42 years. Of the 
319 patients who reported having liver biopsy completed, 
34.5% had early fibrosis, 32.1% had advanced fibrosis, and 
34% did not know the stage of fibrosis reported on most 
recent biopsy.
Immunosuppressant Therapy for AIH
At the time of the survey, 88.1% of patients were on immu-
nosuppressive medications: 35.2% on prednisone, 12.4% 
on budesonide, 52.3% on azathioprine (AZA), 6.5% on 
6-mercaptopurine (6-MP), 13.2% on mycophenolate 
mofetil (MMF), 4.6% on tacrolimus, 0.8% on sirolimus, 
1.1% on cyclosporine (CSA), and 12.4% on ursodeoxy-
cholic acid (UDCA). In total, 198 participants (53.4%) 
were on at least on one immunosuppressant, and 129 
(34.8%) were on more than one. There were 118 partici-
pants (31.8%) on two immunosuppressants, 10 (2.7%) on 
three, and 1 (0.3%) on four. Among participants taking 
more than two immunosuppressants, 99 (76.7%) were tak-
ing a combination of steroid and a thiopurine (AZA or 
6-MP), 25 (19.3%) a combination of steroid and MMF. 
Only 12 patients were taking more than one immunosup-
pressant beyond steroids: 4 (33.3%) on tacrolimus and 
MMF, 4 (33.3%) on tacrolimus and AZA, 1 (8.3%) tac-
rolimus and AZA and sirolimus, 2 (16.7%) CSA and AZA, 
and 1 (8.3%) CSA and MMF.
There were 44 participants (11.9%) not on immunosup-
pression at the time of the survey, of these, and 35 (79.5%) 
had been treated previously with immunosuppression. 
Among all participants, former immunosuppression regi-
mens had included prednisone (224, 60.4%), budesonide 
(56, 15.1%), AZA (117, 31.5%), 6-MP 14 (3.8%), MMF 
32 (8.6%), tacrolimus 10 (2.7%), sirolimus 2 (0.5%), and 
CSA 9 (2.4%).
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CBD Therapy
In total, 93 (25.1%) patients reported they had ever used 
CBD for the treatment of AIH or its perceived symptoms 
(Fig. 1). Ever CBD users were similar to never CBD users; 
however, ever users tended to be female (p < 0.09) and 
have lower household incomes (p < 0.07) (Table 2). Ever 
CBD users were also more likely not to be taking any 
other therapy for the treatment of AIH (12.9% vs. 6%, 
p = 0.035). In total, 278 (74.9%) participants reported 
they never used CBD because of high cost (18.3%) or 
they never heard of it (17.6%), but also worried about 
positive drug screening (10.4%), local laws (9.7%), side 
effects (4.7%), effectiveness (3.2%), and moral or religious 
issues (3.2%). Knowledge about CBD use was attributed 
to information from social media (78.5%), family/friends 
(69.9%), other patients (24.7%), doctors (20.4%), and other 
media (19.4%).
Among ever CBD users, 55 (59%) were current users for 
the treatment of AIH and 38 (41%) were prior users. Among 
ever users, 45.7% reported their treating doctors were aware 
of their CBD use at the time of use. The most frequent AIH 
symptoms treated by participants with CBD were poor sleep 
(66.7%), pain (66.7%), fatigue (44.1%), “liver inflammation” 
(29%), and itch (10.8%). Survey participants reported CBD 
used resulted in significant improvement in sleep (54/59, 
93%), pain (55/63, 87.3%), fatigue (25/38, 65.8%), “liver 
Table 1  Demographics and selected characteristics of AIH patients 
who participated in the current survey
AIH participants (n = 371)
Age at survey completion (years) 49 (38, 59)
Age at AIH diagnosis (years) 42 (30, 52.25)
Race
 Caucasian 88.9%
 Hispanic 3.2%
 Black 2.2%
 Multiple 2.4%
 Other 2.4%
Gender, % female 91.4%
Continent
 North America 81.4%
 Europe 14.3%
 Australia 2.2%
 Asia 0.5%
 South America 0.8%
North America
 USA 76.8%
 Canada 4.6%
Gross household income/year
 < $20,000 9.4%
 $20,001–$50,000 27.0%
 $50,001–$100,000 32.6%
 $100,001–$150,000 18.6%
 > $150,000 11.4%
Level of education
 GED 13.7%
 Bachelor’s degree 24.5%
 Graduate degree 19.0%
 Some college 32.1%
 Technical school 8.1%
 Some high school 1.6%
Fibrosis on biopsy
 F1 18.9%
 F2 15.8%
 F3 19.7%
 F4 12.8%
 Don’t know 28.6%
 No biopsy completed 3.5%
Current medication
 Prednisone 35.3%
 Budesonide 12.4%
 6-Mercaptopurine 6.5%
 Azathioprine 52.3%
 Mycophenolate mofetil 13.2%
 Tacrolimus 4.6%
 Cyclosporine 1.1%
 Sirolimus 0.8%
 Ursodeoxycholic acid 12.4%
 None 11.9%
Fig. 1  Survey completion and CBD use among AIH patients
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inflammation” (27/32, 84.4%), and itch (7/8, 87.5%). Sev-
enteen (18.3%) ever CBD users reported they were able to 
stop or reduce a prescription medication because of CBD 
use. Drug classes reduced or stopped included pain (11/17; 
5 narcotics, 4 NSAIDs, two other), immunosuppressants 
(4/17; 3 steroids, 1 AZA), anxiolytics (3/17; 2 lorazepam, 
one diazepam), antidepressants (1/17; sertraline), and seda-
tives (1/17; zolpidem).
CBD was administered most frequently via sublingual 
drops (55.9%), oral capsule (32.3%), inhalation (28%), 
and topically (12.9%). Only a minority of participants 
reported characteristics of CBD dose (29%). Among 
Table 2  Demographics and 
selected characteristics of AIH 
patients according to CBD ever 
versus never use
CBD ever CBD never p
Age at survey completion, median (Q1, Q3) 47 (37.5, 58) 50 (38, 60) 0.21
Age at AIH diagnosis, median (Q1, Q3) 42 (30, 50) 42 (30, 53) 0.78
Race
 Caucasian 87.10% 89.90% 0.66
 Hispanic 2.20% 3.60%
 Black 2.20% 2.20%
Gender
 Female 95.70% 90% 0.09
 Male 4.30% 10%
Continent
 North America 81% 83.50% 0.45
 Europe 18.30% 13.10%
 Australia 1.10% 2.60%
 South America 0.00% 1.10%
North America
 USA 77.40% 76.60% 0.76
 Canada 3.20% 5%
Gross household income/year
 < $20,000 9.70% 9.90% 0.07
 $20,001–$50,000 36.50% 24.50%
 $50,001–$100,000 36.50% 32.10%
 $100,001–$150,000 3.33% 21.50%
  > $150,000 8.60% 12.40%
Level of education
 GED 11.80% 14.40% 0.31
 Bachelor’s degree 21.50% 25.50%
 Graduate degree 14% 21.20%
 Some college 40.10% 29.60%
 Technical school 9.70% 7.70%
 Some high school 2.20% 1.50%
Fibrosis on biopsy
 F1 18.30% 19.40% 0.38
 F2 19.40% 14.70%
 F3 24.70% 18%
 F4 11.80% 13.20%
Current medical treatment for AIH
 Prednisone 39.80% 33.80% 0.3
 Budesonide 12.90% 12.20% 0.87
 6-Mercaptopurine 7.50% 6.10% 0.63
 Azathioprine 41.90% 55.80% 0.02
 Mycophenolate mofetil 14.00% 12.90% 0.8
 Tacrolimus 4% 5.40% 0.67
 None 12.90% 6.10% 0.035
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reported dosing information, the median dose was 20 mg 
(5 mg, 200 mg), the median daily frequency was 1 (1, 
2), and total daily dose was 25.5 mg (4.8 mg, 87.5 mg). 
The median duration of CBD use among current CBD 
users was 3.5 months (1, 6) and was significantly more 
than prior CBD users (1 month (1, 3), p = 0.007). The 
most common cause for stopping CBD was cost (50%), 
worry about positive drug test (10.5%), side effects 
(10.5%), ineffective (7.9%), the doctor advised against 
CBD (7.9%), and change in the law (7.1%). There was no 
difference in the various demographics and medication 
usage between ever CBD users in either of the histology 
groups (Table 3).
Serious side effects attributed to CBD therapy were 
reported by three participants (3.2%) and included: hun-
ger (1), dry mouth (1), red eyes (1), euphoria (1), and 
itchiness (1). Two participants reported side effects were 
significant enough to seek their doctor’s advice, but 
there were no emergency room visits or hospitalizations 
reported.
Discussion
CBD has been used to treat various symptoms in the gastro-
enterology field with variable outcomes [17–20], yet its use 
among patients with chronic liver disease remains unknown 
[21]. In the current study, we observed that 25% of study 
participants reported ever CBD use directed at the most fre-
quent AIH-related extrahepatic symptoms: pain, sleep, and 
fatigue. Females and those with lower household incomes 
were more likely to have used CBD, yet many patients 
reported their treating doctor was unaware of their use. A 
majority of ever CBD users saw significant improvement in 
targeted symptoms with CBD use and very few experienced 
severe side effects.
The FDA, when supported by rigorous scientific research, 
has endorsed medical use of marijuana-derived products 
as drugs for the treatment of disease. Extrapolating the 
approval of a purified CBD derived from marijuana for 
a seizure disorder to hemp-derived use of CBD to treat a 
variety of symptoms can be serious, unproven, risky, and 
dangerous. Furthermore, in the Epidiolex-treated patients in 
Table 3  Demographics and selected characteristics of AIH patients stratified by fibrosis according to CBD ever versus never use
Advanced fibrosis (n = 119) Non-advanced (n = 126)
CBD ever n = 34 CBD never n = 85 p CBD ever n = 34 CBD never n = 92 p
Age at survey completion (years) 47 (33, 59) 47 (35, 59) 0.48 50.5 (37, 59) 49.5 (37, 59) 0.99
Age at AIH diagnosis (years) 35.5 (25, 54) 43 (25, 54) 0.49 45 (32, 50) 42.5 (31, 52) 0.83
Race, % Caucasian 79.40% 87.10% 0.34 100% 92.40% 0.44
Gender, % female 97.10% 91.70% 0.44 94.10% 88% 0.26
Continent, % North American 79.40% 80% 0.8 82.40% 75% 0.35
Current medication
 Prednisone 41.20% 37.60% 0.84 38% 34.70% 0.83
 Budesonide 8.80% 3.50% 0.35 23.50% 16.30% 0.44
 6-MP 5.90% 8.80% 0.69 11.80% 2.20% 0.73
 Azathioprine 41.20% 56.50% 0.1 44.10% 54.30% 0.32
 Mycophenolate mofetil 17.60% 12.90% 0.57 5.90% 18.50% 0.09
 Tacrolimus 8.80% 5.90% 0.69 5.90% 4.30% 0.01
 Cyclosporine 2.90% 0.00% 0.29 0.00% 2.20% 0.39
 Sirolimus 2.90% 0.00% 0.29 0.00% 2.20% 0.39
 Ursodeoxycholic acid 26.50% 14.10% 0.12 20.60% 9.80% 0.13
 None 10.60% 11.80% 1 20.60% 7.60% 0.05
Symptoms treated with CBD
 Poor sleep 67.60% – – 55.90% – 0.45
 Pain 64.70% – – 67.40% – 1
 Fatigue 35.30% – – 38.20% – 1
 Inflammation 38.10% – – 20.60% – 0.18
 Itch 11.80% – – 8.80% – 1
Serious side effects 2.90% – – 2.90% – 1
 ER visits 0.00% – – 0.00% – 1
 Hospitalizations 0.00% – – 0.00% – 1
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the clinical trials, sleepiness, sedation, and lethargy; elevated 
liver enzymes; decreased appetite; diarrhea; rash; fatigue, 
malaise and weakness, insomnia, sleep disorder, and poor 
quality sleep; and infections were reported. Therefore, the 
CBD use among the patients with AIH as evidenced by the 
survey respondents is concerning. The usage varied equally 
among the age groups and liver fibrosis staging suggest-
ing no rationale or vulnerability of specific demographics 
or disease phenotype from illegal marketing. Depending on 
the percentage of THC in a product and frequency of use, a 
positive urine drug screen for cannabinoids is possible. This 
observation could pose a significant hindrance for patients 
undergoing liver transplant evaluation for end-stage liver 
disease associated with AIH.
CBD, a potent inhibitor of CYP3A4 and CYP2C19, can 
target a variety of channels and receptors including human 
TRP and voltage-gated channels, serotonin receptors 
5-HT1A and 5-HT2A, and G-coupled protein and adenosine 
receptors [22]. Data on drug interactions in human subjects 
taking CBD are scarce; however, we hypothesize that there 
is risk of altered pharmacokinetics in CBD or concurrently 
administered drugs undergoing metabolism via these CYP 
systems. The steroid drug class and calcineurin inhibitors 
[30], metabolized via CYP3A4, are of significant concern 
given 177 patients (47.7%) of study respondents reported 
current use of either prednisone or budesonide and 21 
patients (5.7%) reported use of either tacrolimus or cyclo-
sporine. The relative infrequency that patients did not report 
CBD use to their treating doctors (45.7%) and product vari-
ability across manufacturers [23, 24], dose [21], and route 
[25] of administration could further expand this risk.
No published data encapsulate CBD use across popula-
tions, yet the frequency of CBD use reported in our study is 
similar to that observed among adults with liver disease in 
the USA using other complementary and alternative medi-
cines [26]. Health-related quality of life in AIH is signifi-
cantly reduced [27, 28]; thus, the use of CBD by patients 
to mitigate symptoms attributed to AIH outside the liver is 
not surprising. A majority of patients reported significant 
improvement in AIH-related indications for use (pain, poor 
sleep, fatigue, and itch) which included very few serious side 
effects. Other data about the improvement in these symp-
toms and safety profiles within other CBD-treated popula-
tions are unavailable, but our observations are congruent 
with a meta-analysis that assessed all cannabinoids for medi-
cal use [20].
We readily admit the possible limitation of patient-
reported disease and CBD use data in this study. Histori-
cally, we have shown that AIH patients participating in 
similar research approaches exhibit excellent diagnosis 
agreement when compared to their medical records [15] as 
well as similar demographics and disease attributes [16]. 
However, we also believe there are tremendous benefits to 
treating physicians and patients allowed by rapid recruit-
ment and dissemination of research regarding emerging and 
popular healthcare trends [29]. Furthermore, the anonym-
ity offered through social media may allow for unbiased 
answers for a sensitive topic such as CBD use. CBD has 
been recently showing up in everything from beauty creams 
and bath bombs to vape pens, seltzer, and snacks; thus, our 
survey may underestimate total CBD use among patients. 
Furthermore, attribution of all reported extrahepatic symp-
tom improvement to CBD use in our study is inappropri-
ate, as we did not collect other interventions or exposures 
(marijuana, other over the counter supplements, meditation, 
etc.) that may have been completed concurrently with CBD.
In summary, CBD use in our online cohort was com-
mon and associated with a significant improvement in AIH-
related symptoms and side effects of immunosuppressant 
medications. The overall positive therapeutic benefits from 
this study as well as the observation of few serious side 
effects would be supportive of future trials (possibly with 
cannabinoids) aimed at improving health-related quality of 
life in AIH patients. Strict regulation of product formulation 
and dose and well as further examination of CBD pharma-
cokinetics would help alleviate safety concerns in patients 
taking a wide variety of pharmaceuticals.
Funding Funding was provided by National Institute of Diabetes and 
Digestive and Kidney Diseases (Grant No. DK114561).
Compliance with Ethical Standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution-NonCommercial 4.0 International License 
(http://creat iveco mmons .org/licen ses/by-nc/4.0/), which permits any 
noncommercial use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons license, and indicate 
if changes were made.
References
 1. Heneghan MA, Yeoman AD, Verma S, et al. Autoimmune hepa-
titis. Lancet. 2013;382:1433–1444.
 2. EASL Clinical Practice Guidelines. Autoimmune hepatitis. J 
Hepatol. 2015;63:971–1004.
 3. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and manage-
ment of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.
 4. Takahashi A, Moriya K, Ohira H, et al. Health-related quality of 
life in patients with autoimmune hepatitis: a questionnaire survey. 
PLoS ONE. 2018;13:e0204772.
 5. Vuppalanchi V, Chalasani S, Mohammad S, et al. Patient reported 
outcomes of physical and psychological suffering in patients with 
328 Digestive Diseases and Sciences (2020) 65:322–328
1 3
autoimmune hepatitis. In: American College of Gastroenterology. 
October 5–10, 2019, Philadelphia. Abstract #P2376.
 6. Janik MK, Wunsch E, Raszeja-Wyszomirska J, et al. Autoim-
mune hepatitis exerts a profound, negative effect on health-
related quality of life: a prospective, single-centre study. Liver 
Int. 2019;39:215–221.
 7. van der Plas SM, Hansen BE, de Boer JB, et al. Generic and 
disease-specific health related quality of life of liver patients with 
various aetiologies: a survey. Qual Life Res. 2007;16:375–388.
 8. Bishop FL, Lewith GT. Who uses CAM? A narrative review 
of demographic characteristics and health factors associated 
with CAM use. Evid Based Complement Altern Med eCAM. 
2010;7:11–28.
 9. Barnes PM, Powell-Griner E, McFann K, et al. Complementary 
and alternative medicine use among adults: United States. Adv 
Data. 2002;2004:1–19.
 10. O’Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-
resistant epilepsy: a review. Epilepsy Behav. 2017;70:341–348.
 11. Hasenoehrl C, Storr M, Schicho R. Cannabinoids for treating 
inflammatory bowel diseases: Where are we and where do we 
go? Expert Rev Gastroenterol Hepatol. 2017;11:329–337.
 12. Kafil TS, Nguyen TM, MacDonald JK, et al. Cannabis for the 
treatment of Crohn’s disease. Cochrane Database Syst Rev. 
2018;11:Cd012853.
 13. Schumacher KR, Stringer KA, Donohue JE, et  al. Social 
media methods for studying rare diseases. Pediatrics. 
2014;133:e1345–e1353.
 14. Chalasani S, Vuppalanchi V, Tilmans L, et al. Novel approach 
leveraging social media indicates complementary and alternative 
medicine use highly prevalent and is sometimes associated with 
serious adverse events in patients with autoimmune hepatitis. 
American Journal of Gastroenterology. 2018;113:S526.
 15. Comerford M, Fogel R, Bailey JR, et al. Leveraging social net-
working sites for an autoimmune hepatitis genetic repository: pilot 
study to evaluate feasibility. J Med Internet Res. 2018;20:e14.
 16. Fogel R, Comerford M, Chilukuri P, et al. Extrahepatic autoim-
mune diseases are prevalent in autoimmune hepatitis patients 
and their first-degree relatives: survey study. Interact J Med Res. 
2018;7:e18.
 17. Izzo AA, Camilleri M. Emerging role of cannabinoids in gas-
trointestinal and liver diseases: basic and clinical aspects. Gut. 
2008;57:1140–1155.
 18. Naftali T, Lev LB, Yablecovitch D, et al. Treatment of Crohn’s 
disease with cannabis: an observational study. Isr Med Assoc J. 
2011;13:455–458.
 19. Naftali T, Bar-Lev Schleider L, Dotan I, et al. Cannabis induces 
a clinical response in patients with Crohn’s disease: a prospec-
tive placebo-controlled study. Clin Gastroenterol Hepatol. 
2013;11(1276–1280):e1.
 20. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for 
medical use: a systematic review and meta-analysis. JAMA. 
2015;313:2456–2473.
 21. Goyal H, Rahman MR, Perisetti A, et  al. Cannabis in liver 
disorders: a friend or a foe? Eur J Gastroenterol Hepatol. 
2018;30:1283–1290.
 22. Rong C, Carmona NE, Lee YL, et al. Drug-drug interactions as 
a result of co-administering delta(9)-THC and CBD with other 
psychotropic agents. Expert Opin Drug Saf. 2018;17:51–54.
 23. Peace MR, Butler KE, Wolf CE, et al. Evaluation of two com-
mercially available cannabidiol formulations for use in electronic 
cigarettes. Front Pharmacol. 2016;7:279.
 24. Bonn-Miller MO, Loflin MJE, Thomas BF, et  al. Labe-
ling accuracy of cannabidiol extracts sold online. JAMA. 
2017;318:1708–1709.
 25. Huestis MA. Human cannabinoid pharmacokinetics. Chem Bio-
divers. 2007;4:1770–1804.
 26. Henson JB, Brown CL, Chow SC, et al. Complementary and alter-
native medicine use in United States adults with liver disease. J 
Clin Gastroenterol. 2017;51:564–570.
 27. Wong LL, Fisher HF, Stocken DD, et al. The impact of autoim-
mune hepatitis and its treatment on health utility. Hepatology. 
2018;68:1487–1497.
 28. Schramm C, Wahl I, Weiler-Normann C, et al. Health-related 
quality of life, depression, and anxiety in patients with autoim-
mune hepatitis. J Hepatol. 2014;60:618–624.
 29. Kulanthaivel A, Fogel R, Jones J, et al. Digital cohorts within the 
social mediome: an approach to circumvent conventional research 
challenges? Clin Gastroenterol Hepatol. 2017;15:614–618.
 30. Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway 
RR. Evidence of a clinically significant drug–drug interaction 
between cannabidiol and tacrolimus. Am J Transplant. 2019. https 
://doi.org/10.1111/ajt.15398 .
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
